Merck last week agreed to pay nearly $5 billion to settle most of the claims generated by its nowwithdrawn painkiller Vioxx, said Matthew Herper and Robert Langreth in Forbes.com. Plaintiffs ...

But this will be greatly reduced by state law. The legal experts say that the verdict is a weak case against Vioxx maker Merck & Co. Inc. The jury awarded Leonel Garza's family $7 million in ...

In previous high-profile litigation, Merck agreed in 2007 to pay almost $5 billion to settle personal injury suits claiming that its recalled pain drug Vioxx caused heart attacks and strokes.

Merck argues shareholders, who filed suit in November 2003, waited too long to sue. The case, involving the drug Vioxx, could have far-reaching impact, as the question presented was when ...

Co. withdrew the painkiller Vioxx from the market last September after the drug was linked to increased risks of heart attack and stroke, more than one metabolomics researcher shook their heads and ...

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account. We offer one free story view per month. If you ...

Triggered by concerns over an increased risk of cardiovascular side effects, Merck announced on 30 September the withdrawal of rofecoxib (Vioxx), its leading drug for the management of rheumatoid ...

The ADVANTAGE (Assessment of Differences between Vioxx And Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness) trial was devised by Merck´s marketing division in January 1999 ...

The most popular of these were Vioxx (Merck) and Celebrex (Pfizer). We studied how prescriptions for these two drugs for patients with osteoarthritis responded to changes in television advertising ...